Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $13,551 - $20,661
-232 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $1,151 - $1,748
-28 Reduced 10.77%
232 $14,000
Q2 2020

Aug 12, 2020

SELL
$25.95 - $43.15 $181 - $302
-7 Reduced 2.62%
260 $11,000
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $156 - $463
-6 Reduced 2.2%
267 $8,000
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $60 - $154
1 Added 0.37%
273 $20,000
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $264,727 - $358,454
-1,887 Reduced 87.4%
272 $38,000
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $259,347 - $300,816
1,643 Added 318.41%
2,159 $395,000
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $893 - $1,636
-10 Reduced 1.9%
516 $82,000
Q4 2018

Jan 31, 2019

SELL
$81.94 - $139.71 $3,113 - $5,308
-38 Reduced 6.74%
526 $50,000
Q3 2018

Nov 15, 2018

BUY
$138.11 - $169.04 $3,867 - $4,733
28 Added 5.22%
564 $80,000
Q2 2018

Aug 22, 2018

SELL
$140.36 - $175.76 $21.4 Million - $26.8 Million
-152,718 Reduced 99.65%
536 $84,000
Q2 2018

Aug 15, 2018

BUY
$140.36 - $175.76 $21.5 Million - $26.9 Million
153,254 New
153,254 $84,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.